GlassScriptPhysician profile
Alexandr Babayeuski
NPI 1013168558
$9,194.44
in general payments reported to CMS, 2019-2025
25 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $308 · 2021: $462 · 2022: $526 · 2023: $849 · 2024: $5,009 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $3,500 · Food and Beverage: $3,336 · Gift: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $3,500.00 |
| Food and Beverage | $3,336.10 |
| Gift | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exo Imaging, INC. | $3,550.00 | 2024 | Exo Iris |
| Janssen Pharmaceuticals, INC | $1,090.33 | 2019-2024 | Xarelto |
| Pfizer INC. | $815.04 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $650.00 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $480.78 | 2019-2025 | Breztri, Airsupra, Lokelma |
| Ucb, INC. | $412.81 | 2022-2025 | Briviact |
| Abbvie INC. | $335.87 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $219.43 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.07 | 2019-2024 | Jardiance, Stiolto Respimat |
| Mallinckrodt Hospital Products INC. | $190.69 | 2024-2025 | Terlivaz |
| Merck Sharp & Dohme LLC | $176.40 | 2019-2024 | Verquvo |
| Novo Nordisk INC | $174.45 | 2020-2024 | |
| Gilead Sciences, INC. | $155.52 | 2023-2025 | Veklury |
| Lilly USA, LLC | $124.98 | 2024 | Zepbound |
| Xeris Pharmaceuticals, INC. | $115.84 | 2023-2025 | Gvoke Hypopen |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $107.01 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $91.93 | 2019-2023 | Eliquis |
| Inari Medical, INC. | $76.79 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Alexion Pharmaceuticals, INC. | $62.68 | 2019-2021 | |
| Allergan, INC. | $47.32 | 2019 | |
| Genzyme Corporation | $45.94 | 2024 | |
| Bioxcel Therapeutics, INC. | $20.49 | 2023 | Igalmi |
| Nabriva Therapeutics, Plc | $19.35 | 2020 | |
| Stryker Corporation | $18.71 | 2025 | Ivas |
| Otsuka America Pharmaceutical, INC. | $18.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandr Babayeuski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.